LCM
INSY

Landscape Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Landscape Capital Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-28,650
Closed -$254K – 817
2017
Q3 		$254K Buy
+28,650
New +$296K 0.03% 423
2015
Q2 		– Sell
-20,000
Closed -$581K – 806
2015
Q1 		$581K Buy
+20,000
New +$529K 0.16% 170

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Landscape Capital Management's INSY Position: Q4 2017 in Review

Landscape Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q4 2017, closing a stake of 28,650 shares — an estimated $254K sold.

Landscape Capital Management first reported a position in INSY in Q1 2015 and held it in 2 quarters. The position peaked at $581K in Q1 2015. 112 funds tracked by Wall St. Rank hold INSY as of Q4 2017.

  • Landscape Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Landscape Capital Management sold 28,650 Insys Therapeutics, Inc. shares in Q4 2017, an estimated $254K.
  • Landscape Capital Management first reported a position in Insys Therapeutics, Inc. in Q1 2015 and held it in 2 quarters.
  • Landscape Capital Management's Insys Therapeutics, Inc. position peaked at $581K in Q1 2015.
  • 112 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2017.

Based on Landscape Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.